Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENGN NASDAQ:EPRX NASDAQ:GNFT NASDAQ:INKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENGNenGene$3.68+3.1%$3.60$2.65▼$11.00$182.45M-0.41103,106 shs29,863 shsEPRXEupraxia Pharmaceuticals$5.26-2.4%$4.93$2.20▼$6.20$193.64M1.511,039 shs5,124 shsGNFTGENFIT$3.75+0.8%$3.93$2.55▼$6.42$186.26M1.142,838 shs16,482 shsINKTMiNK Therapeutics$12.06-4.7%$13.15$4.56▼$76.00$50.46M0.333.03 million shs175,191 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENGNenGene-7.99%-5.80%-6.79%+20.61%-49.22%EPRXEupraxia Pharmaceuticals-1.09%-0.72%-4.10%+41.08%+123.38%GNFTGENFIT+2.83%-0.65%+3.53%-11.40%-6.16%INKTMiNK Therapeutics-3.06%-16.49%+75.83%+80.09%+50.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENGNenGene3.2763 of 5 stars3.55.00.00.01.82.50.6EPRXEupraxia Pharmaceuticals2.7515 of 5 stars3.62.00.00.03.20.00.6GNFTGENFIT1.7367 of 5 stars3.53.00.00.02.10.00.0INKTMiNK Therapeutics2.4293 of 5 stars3.42.00.00.02.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENGNenGene 3.00Buy$23.29532.76% UpsideEPRXEupraxia Pharmaceuticals 3.17Buy$11.00109.13% UpsideGNFTGENFIT 3.00Buy$13.00246.67% UpsideINKTMiNK Therapeutics 2.75Moderate Buy$37.50210.95% UpsideCurrent Analyst Ratings BreakdownLatest INKT, ENGN, GNFT, and EPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025EPRXEupraxia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$11.007/18/2025INKTMiNK TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.007/11/2025INKTMiNK TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform6/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/16/2025EPRXEupraxia PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSpeculative Buy(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENGNenGeneN/AN/AN/AN/A$5.35 per shareN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AN/AGNFTGENFIT$76.77M2.44$0.07 per share53.26$1.50 per share2.50INKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENGNenGene-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%9/10/2025 (Estimated)EPRXEupraxia Pharmaceuticals-$25.50M-$0.76N/AN/AN/AN/A-367.73%-112.23%N/AGNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/AN/AINKTMiNK Therapeutics-$9.51M-$2.52N/AN/AN/AN/AN/A-140.72%8/14/2025 (Estimated)Latest INKT, ENGN, GNFT, and EPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025INKTMiNK Therapeutics-$0.45N/AN/AN/AN/AN/A6/10/2025Q2 2025ENGNenGene-$0.4768-$0.51-$0.0332-$0.51N/AN/A5/15/2025Q1 2025INKTMiNK Therapeutics-$0.61-$0.70-$0.09-$0.70N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENGNenGeneN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENGNenGene0.0912.6612.66EPRXEupraxia PharmaceuticalsN/A11.1011.10GNFTGENFIT0.081.231.23INKTMiNK TherapeuticsN/A0.300.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENGNenGene64.16%EPRXEupraxia PharmaceuticalsN/AGNFTGENFIT2.24%INKTMiNK Therapeutics2.87%Insider OwnershipCompanyInsider OwnershipENGNenGene10.40%EPRXEupraxia PharmaceuticalsN/AGNFTGENFIT4.20%INKTMiNK Therapeutics22.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENGNenGene3151.10 million45.79 millionN/AEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/AGNFTGENFIT12050.00 million47.90 millionNot OptionableINKTMiNK Therapeutics303.99 million3.09 millionNo DataINKT, ENGN, GNFT, and EPRX HeadlinesRecent News About These CompaniesMiNK Therapeutics (INKT) Projected to Post Earnings on ThursdayAugust 7 at 2:34 AM | marketbeat.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Large Increase in Short InterestAugust 2, 2025 | marketbeat.comMink Therapeutics Inc News (INKT) - Investing.comAugust 1, 2025 | investing.comMiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial ReportJuly 31, 2025 | globenewswire.comLongbow Finance SA Reduces Holdings in MiNK Therapeutics, Inc. (NASDAQ:INKT)July 26, 2025 | marketbeat.comMiNK Therapeutics (NASDAQ:INKT) Upgraded to Strong-Buy at B. RileyJuly 19, 2025 | marketbeat.comMiNK Therapeutics: Moving Out Of The Hunt's Early DaysJuly 16, 2025 | seekingalpha.comWilliam Blair Downgrades MiNK Therapeutics (INKT)July 16, 2025 | msn.comHC Wainwright Reiterates Neutral Rating for MiNK Therapeutics (NASDAQ:INKT)July 15, 2025 | marketbeat.comMiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell TherapyJuly 15, 2025 | globenewswire.comMiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell TherapyJuly 15, 2025 | globenewswire.comMiNK Therapeutics Enters $50M Sales Agreement with B. RileyJuly 15, 2025 | tipranks.comMiNK Therapeutics Shares Drop Sharply Following William Blair DowngradeJuly 14, 2025 | msn.comMiNK Therapeutics stock falls after William Blair downgradeJuly 14, 2025 | finance.yahoo.comPromising Small Cap Stocks To Watch Now - July 13thJuly 13, 2025 | marketbeat.comPharmaceutical Stocks Worth Watching - July 13thJuly 13, 2025 | marketbeat.comMiNK Therapeutics Announces Publication of Complete Remission Following ...July 13, 2025 | seekingalpha.comMiNK Therapeutics: AgenT-797 Solidifies Itself As iNKT Cell Therapy With Latest CR DataJuly 13, 2025 | seekingalpha.comPromising Medical Stocks To Add to Your Watchlist - July 13thJuly 13, 2025 | marketbeat.comWhy Is MiNK Therapeutics Stock (INKT) Up 190% Today?July 12, 2025 | msn.comMiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell ...July 11, 2025 | bakersfield.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINKT, ENGN, GNFT, and EPRX Company DescriptionsenGene NASDAQ:ENGN$3.68 +0.11 (+3.08%) Closing price 04:00 PM EasternExtended Trading$3.76 +0.07 (+2.04%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Eupraxia Pharmaceuticals NASDAQ:EPRX$5.26 -0.13 (-2.41%) Closing price 04:00 PM EasternExtended Trading$5.26 +0.00 (+0.10%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.GENFIT NASDAQ:GNFT$3.75 +0.03 (+0.81%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.MiNK Therapeutics NASDAQ:INKT$12.06 -0.60 (-4.74%) Closing price 04:00 PM EasternExtended Trading$11.92 -0.14 (-1.13%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
